Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. With Xofigo (or radium Ra 223 dichloride), you can get relief from the bone pain that makes moving difficult and. Examples of radioactive injections are strontium 89 and radium-223 (Alpharadin / Xofigo (zo-fee-go). Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. But we can treat it with a radioactive drug. Radium-223 is an appropriate treatment for patients with mCRPC with a median overall survival of 27.4 months and a drug-free interval of 30 weeks after six cycles of radium-223. Radioactive injections will not lower your PSA. Of the 26 patients who completed all six cycles, sixteen patients started another line of treatment for mCRPC after a median time of 30.0 weeks (95% CI: 18.1-NA) after the last injection of radium-223. Patients who completed all six cycles had a median survival time of 27.4 months (95% CI: 16.4-non applicable ) and patients who completed one to four cycles 9.0 months (95% CI: 4.6-NA, log rank test: p<0.001). And, one patient who stopped treatment after five cycles was lost to follow up. The reasons for discontinuing treatment early were progressive disease during treatment with radium-223 (four patients) myelotoxicity (one patient, who was previously treated for a small cell carcinoma of the ureter with six cycles of carboplatinum) intercurrent death due to non-prostate cancer-related diseases (four patients) patient refusal (one patient) complication due to co-morbid condition (one patient). Radiation therapy for stage 4 prostate cancer uses a large machine that moves around your body, directing energy beams to the area around the cancer (external beam radiation therapy). A total of 26 patients (68.4%) completed all six cycles of radium-223, while twelve patients (31.6%) stopped treatment earlier. Background Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. ![]() The Kaplan-Meier method was used to describe overall survival, and the log-rank was used to compare different groups. In this retrospective study, the experience with radium-223 in patients with mCRPC, treated in a single centre, is reported in relation to the number of cycles of radium-223 given reason of discontinuing radium-223 treatment, overall survival according to radium-223 treatments received next treatment and interval to next treatment after discontinuing radium-223. ![]() ![]() Radium-223 is one of the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), based on the ALSYMPCA trail, a large randomised study.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |